The combined effect of adiponectin and resistin on all-cause mortality in patients with type 2 diabetes: Evidence of synergism with abdominal adiposity

MLA

Claudia Menzaghi, et al. “The Combined Effect of Adiponectin and Resistin on All-Cause Mortality in Patients with Type 2 Diabetes: Evidence of Synergism with Abdominal Adiposity.” Atherosclerosis, vol. 250, July 2016, pp. 23–29. EBSCOhost, https://doi.org/10.1016/j.atherosclerosis.2016.04.028.

APA

Claudia Menzaghi, Massimiliano Copetti, Concetta De Bonis, Andrea Fontana, Mauro Cignarelli, Lucia Salvemini, Lorena Ortega Moreno, Olga Lamacchia, & Vincenzo Trischitta. (2016). The combined effect of adiponectin and resistin on all-cause mortality in patients with type 2 diabetes: Evidence of synergism with abdominal adiposity. Atherosclerosis, 250, 23–29. https://doi.org/10.1016/j.atherosclerosis.2016.04.028

Chicago

Claudia Menzaghi, Massimiliano Copetti, Concetta De Bonis, Andrea Fontana, Mauro Cignarelli, Lucia Salvemini, Lorena Ortega Moreno, Olga Lamacchia, and Vincenzo Trischitta. 2016. “The Combined Effect of Adiponectin and Resistin on All-Cause Mortality in Patients with Type 2 Diabetes: Evidence of Synergism with Abdominal Adiposity.” Atherosclerosis 250 (July): 23–29. doi:10.1016/j.atherosclerosis.2016.04.028.